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Abstract
Background: Mesenchymal stromal cells (MSC) possess immunomodulatory properties and low immunogenicity,
both crucial properties for their development into an effective cellular immunotherapy. They have shown benefit
in clinical trials targeting liver diseases; however the efficacy of MSC therapy will benefit from improvement of the
immunomodulatory and immunogenic properties of MSC.
Methods: MSC derived from human umbilical cords (ucMSC) were treated for 3 days in vitro with
various inflammatory factors, interleukins, vitamins and serum deprivation. Their immunogenicity and
immunomodulatory capacity were examined by gene-expression analysis, surface-marker expressions, IDO
activity, PGE2 secretion and inhibition of T cell proliferation and IFNγ production. Furthermore, their activation
of NK cell cytotoxicity was investigated via CD107a expression on NK cells. The immunomodulatory capacity,
biodistribution and survival of pre-treated ucMSC were investigated in a CCl4-induced liver disease mouse
model. In addition, capacity of pre-treated MSC to ameliorate liver inflammation was examined in an ex vivo
liver inflammation co-culture model.
Results: IFN-γ and a multiple cytokine cocktail (MC) consisting of IFN-γ, TGFβ and retinoic acid upregulated
the expression of immunomodulatory factor PD-L1 and IDO activity. Subsequently, both treatments enhanced
the capacity of ucMSC to inhibit CD4 and CD8 T cell proliferation and IFN-γ production. The susceptibility of
ucMSC for NK cell lysis was decreased by IFN-β, TGFβ and MC treatment. In vivo, no immunomodulation was
observed by the ucMSC. Four hours after intravenous infusion in mice with CCl4-induced inflammatory liver
injury, the majority of ucMSC were trapped in the lungs. Rapid clearance of ucMSC(VitB6), ucMSC(Starv + VitB6)
and ucMSC(MC) and altered bio-distribution of ucMSC(TGFβ) compared to untreated ucMSC was observed. In
the ex vivo co-culture system with inflammatory liver slices ucMSC(MC) showed significantly enhanced
modulatory capacity compared to untreated ucMSC.
Conclusions: The present study demonstrates the responsiveness of ucMSC to in vitro optimisation treatment.
The observed improvements in immunomodulatory capacity as well as immunogenicity after MC treatment
may improve the efficacy of ucMSC as immunotherapy targeted towards liver inflammation.
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Background
Mesenchymal stromal cells (MSC) are a novel therapeutic
option for inflammatory conditions and have been studied
in animal models as well as in preliminary clinical studies
[1–6]. In particular, MSC have shown potential in clinical
trials of patients with liver diseases, such as liver cirrhosis
[7–10] and acute-on-chronic liver failure [11–13]. In
addition, they have shown to be able to modulate the im-
mune system in other various diseases, however, there is
not convincing evidence for all diseases [1]. MSC possess
two immunological properties that make them interesting
candidates for cellular immunotherapy; their immuno-
modulatory capacity and low recognition by the host
immune system. Optimisation of these properties will
enhance their efficacy as immunotherapy.
MSC express a vast range of factors which target
immune cells and influence their function, such as
modulation of B cell and natural killer (NK) cell func-
tion, suppression of T cell proliferation/activation as
well as induction of regulatory T cells (Treg) [14–17].
One of their key immunomodulatory factors is
indoleamine 2,3-dioxygenase (IDO), which deprives
the environment of L-tryptophan thereby inhibiting
lymphocyte proliferation [18], has been demonstrated
to promote graft acceptance after solid organ transplant-
ation [19]. In addition, prostaglandin E2 (PGE2), CCL2
and interleukin 1 receptor antagonist (IL1RA), which are
produced by MSC have shown to have an important role
in the therapeutic effects of MSC on autoimmune dis-
eases, such as rheumatoid arthritis [3, 4, 20–23]. Besides
secretion of anti-inflammatory factors, MSC express cell
surface proteins that are known for their immunoregula-
tory function, such as programmed death-ligand 1 (PD-
L1), which inhibits lymphocyte proliferation [24].
In addition, MSC have low immunogenicity due to low
levels of HLA class I and lack of HLA class II and co-
stimulatory molecule expression on their surface, which
may potentially allow the use of allogeneic MSC for treat-
ment without inducing allogeneic responses [25]. In
addition, complex formation of HLA class I with inhibi-
tory NK cell receptors protects MSC from NK cell lysis
[26]. However, HLA class I enables recognition of MSC by
allogenic CD8+ T cells, and initiation of lysis [26, 27] and
Cho et al. observed IgG antibody responses to allogeneic
umbilical cord tissue-derived stromal cells [28]. Conse-
quently, recognition by immune cells in vivo may reduce
the survival time of MSC and thereby restricting the
duration of their effect [29]. Another in vivo drawback is
that MSC get trapped in the lungs due to their size,
restricting their migration to the site of injury [29, 30].
Improving MSC ex vivo in such a way that their immuno-
genicity is reduced and their immunosuppressive capacity
is enhanced may therefore be beneficial for their survival
as well as their effectiveness after administration.
MSC can be isolated from different tissues in the
body [31], and often constitute a heterogeneous popu-
lation of cells. The use of a more homogeneous MSC
subset, will potentially increase the consistency of
treatment results and improve efficacy. Studies invol-
ving specific MSC subsets, based on selection of MSC
expressing Stro-1, CD73, CD90 or CD271, have
shown that these subsets possess enhanced immuno-
suppressive capacities [32–36]. Recently, a new subset,
identified by the surface marker CD362+ (Syndecan-2)
has been identified (patent number WO 2013117761
A1), which showed improved clonogenicity and im-
munomodulatory properties.
MSC contain an abundance of surface receptors for a
large variety of factors such as inflammatory factors,
interleukins, prostaglandins and several vitamins. Treat-
ment of MSC by such factors, like interferon gamma
(IFN-γ), tumour necrosis factor alpha (TNF-α) and
interleukin 17 (IL-17), induces MSC to adapt towards a
more immunomodulatory phenotype and alters their
immunogenicity [37–39]. In addition, different culture
conditions, such as serum-deprivation and hypoxia [40]
may affect the function of MSC.
In this study, we exposed MSC to various growth
factors, cytokines and culture conditions with the aim to
generate MSC with enhanced properties; reduced im-
munogenicity and improved immunosuppressive capacity,
for immunotherapy to target liver inflammation. Through
analysing surface marker expression, gene expression and
secretome we examined the immunophenotype of pre-
treated MSC. In addition, the immunogenicity and immu-
nomodulatory capacity of pre-treated MSC were evaluated
by their susceptibility to trigger NK cytotoxic activity and
their capacity to inhibit lymphocyte proliferation, respect-
ively. Furthermore, their potential to ameliorate inflamma-
tion and immunomodulate the immune response was
tested in vivo as well as ex vivo in a murine liver inflam-
mation model.
Methods
Culture expansion of ucMSC
Human umbilical cord tissue was collected from Caesarean
section deliveries by Tissue Solutions Ltd. (Glasgow, UK)
from virally screened healthy donors. All such cord was ob-
tained according to legal and ethical requirements of the
UK, with the approval of the relevant ethics committee and
with anonymous consent from the donor. Cords were har-
vested within 48 hours of birth and the average length of
collected umbilical cord tissue (n = 4–6) was 8.6 cm, with
all tissues transported for processing to Orbsen Therapeu-
tics Ltd. in AQIX® solution (London, UK) at 4 °C. In short,
umbilical cord tissue was washed and the whole tissue was
manually dissociated before enzymatic digestion in an en-
zyme cocktail consisting of MEM alpha (Gibco, Thermo
de Witte et al. Stem Cell Research & Therapy  (2017) 8:140 Page 2 of 12
Fisher Scientific, Paisley, UK), collagenase 1 (2 mg/ml),
hyaluronidase 1 (1 mg/ml) and DNase (0.1 mg/ml) (Sigma-
Aldrich, Arklow, Ireland) for a maximum of 2 hours at 37 °
C. Thereafter, a single cell suspension was obtained by
filtration (100 μm) and the cells were stained with CD362
(Syndecan-2/ORB, APC, clone 305515, dilution 1:50, R&D
Systems, Minneapolis, MN, USA) for 30 minutes at 4 °C.
Subsequently, cells were washed and resuspended in MACs
buffer 80 μl/107cells. Next, the cells were incubated with
anti-APC beads (20 μl/107cells, Miltenyi Biotec, GmbH,
Bergisch Gladbach, Germany) for 15 minutes at 4 °C.
CD362+ cells were then isolated using MS MACs column
according to manufacturer’s instructions, (Miltenyi Biotec).
Each cell fraction was counted, seeded for expansion and
cryopreserved at passage 2 for shipment to Erasmus
Medical Center. Here ucMSC were cultured in minimum
essential medium Eagle alpha modification (MEM-α;
Sigma-Aldrich, St. Louis, MO, USA) containing 2 mM L-
glutamine (Lonza, Verviers, Belgium), 1% penicillin/strepto-
mycin solution (P/S; 100 IU/ml penicillin, 100 IU/ml
streptomycin; Lonza) and supplemented with 15% fetal
bovine serum (FBS; Lonza) and 1 ng/ml basic fibroblast
growth factor (bFGF) (Sigma-Aldrich) and kept at 37 °C,
5% CO2 and 20% O2. Medium was changed once a week
and ucMSC were passaged at approximately 80–90% con-
fluence using 0.05% trypsin-EDTA (Life Technologies,
Paisley, UK). All ucMSC used in experiments were between
passage 4 and 7.
Study design
A set of in vitro, in vivo and ex vivo experiments was de-
signed to analyse the effect of pre-treatment of ucMSC
with various growth factors, cytokines and culture con-
ditions, as depicted in Additional file 1: Figure S1 and
described in detail below.
Treatment of ucMSC
UcMSC were treated with (Table 1 and Additional file 2:
Table S1): activin A (12 ng/ml; Miltenyi Biotec GmbH),
budesonide (50 mM; FLUKA Sigma-Aldrich), interferon
gamma (IFN-γ, 50 ng/ml; Life Technologies), interferon
beta (IFN-β, 5 ng/ml; Peprotech, Rocky Hill, NJ, USA),
transforming growth factor beta 1 (TGFβ, 10 ng/ml;
R&D Systems), interleukin-15 (IL-15, 10 ng/ml; Pepro-
tech), interleukin-17 (IL-17, 50 ng/ml; Peprotech), retin-
oic acid (RA, 1 μM and 10 μM; Sigma), trespostinil
(20 ng/ml; Cayman Chemical Company, Ann Arbor, MI,
USA), tumour necrosis factor alpha (TNF-α, 10 ng/ml;
Peprotech), 1α,25-dihydroxyvitamin D3 (vitamin D3,
VitD3; 0.01 μM; Sigma-Aldrich) and pyridoxal hydro-
chloride (vitamin B6, VitB6, 1 μM; Sigma-Aldrich). All
factors were added at day 0 and the cells were analysed
at day 3, except for trespostinil, which due to its instabil-
ity was added daily. In addition, ucMSC were also cul-
tured without serum (starvation, Starv). Two further
combinations were also used: starvation and vitamin B6
(Starv + VitB6) and the multiple cytokine combination
(MC), consisting out of IFN-γ, TGFβ and RA.
Flow cytometric analysis
Flow cytometric characterisation of control and treated
ucMSC was performed by labelling with standard MSC
markers, according to ISSCT criteria [41]: CD13 (PE-
Table 1 Observed changes in immunogenic and immunomodulatory molecules after 3 days in vitro treatment of ucMSC
Immunogenic read out parameters Immunomodulatory read out parameters Fold increase of gene expression
compared to unstimulated
HLA class
I- expressing
cells [%]
HLA class
II- expressing
cells [%]
L-Kynurenine
(correlated IDO
activity) [μM]
PGE2
[ng/ml]
PD-L1- expressing
cells [%]
CD73-expressing
cells [%]
IL-1RA [corrected for GAPDH]
[-] 7 ± 1 10 ± 3 2 ± 5 14 ± 3 46 ± 6 95 ± 2 1 ± 0
IFN-y 60 ± 9* 68 ± 9* 27 ± 10* 1 ± 0* 95 ± 3* 94 ± 3 1 ± 0
IFN-β 36 ± 12* 14 ± 5 10 ± 10 3 ± 2 73 ± 12 91 ± 5 4 ± 1
TGFβ 9 ± 3 10 ± 3 3 ± 1 3 ± 2 58 ± 7 89 ± 5 4 ± 4
Starv 15 ± 3* 4 ± 2 6 ± 3 4 ± 3 24 ± 8* 100 ± 0 1 ± 0
VitB6 47 ± 5
* 34 ± 9* 3 ± 5 12 ± 5 59 ± 14 100 ± 0 67 ± 42
Starv + VitB6 62 ± 7
* 22 ± 5* 0 ± 3 6 ± 3 72 ± 7* 100 ± 0 507 ± 262
RA 26 ± 5* 18 ± 5 0 ± 0 5 ± 2 59 ± 11 98 ± 1 5 ± 4
MC 85 ± 4* 76 ± 7* 29 ± 8* 8 ± 3 97 ± 1* 98 ± 2 3 ± 2
The table displays the mean ± SEM percentages of MSC-expressing surface markers HLA class I and II, PD-L1 and CD73, measured by flow cytometry , the mean ±
SEM concentration of L-Kynurenine [μM] and PGE2 [ng/ml] measured by ELISA and fold increases in IL1RA mRNA expression compared to unstimulated MSC. n = 5
ucMSC umbilical cord-derived mesenchymal stromal cells, HLA human leukocyte antigen, IDO indoleamine 2,3 dioxygenase, PGE2 prostaglandin E2, PD-L1
programmed cell death ligand 1, IL interleukin, IFN-γ interferon gamma, IFN-β interferon beta, TGFβ transforming growth factor beta, Starv starvation, VitB6 Vitamin
B6, pyridoxal hydrochloride, RA retinoic acid, MC multiple cytokine combination
*Indicates p < 0.05
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Cy7, BD Biosciences, San Jose, CA, USA), CD73 (PE, BD
Pharmingen, San Diego, CA, USA), CD90 (APC, R&D
Systems) and CD105 (FITC, R&D Systems), hematopoietic
markers CD31 (PB, BD Biosciences), CD45 (APC-Cy, BD
Biosciences) and the surface markers: HLA class I (Pacific
Blue, Biolegend, San Diego, CA, USA), HLA class II
(PERCP, BD Biosciences), CD362 (APC, R&D Systems),
PD-L1 (PE, Biolegend), CD271 (PE-Cy7, BD Pharmingen),
CD73 (PE, BD Pharmingen) and CD40 (PERCP,
Biolegend).
L-Kynurenine assay
IDO activity was analysed by measuring L-Kynurenine
levels in the supernatants. Supernatant was harvested at
day 3 and centrifuged for 10 minutes at 3000 rpm, to re-
move dead cells. Samples were stored at −80 °C until the
assay was performed. After thawing, samples were spun
down, at 3000 rpm for 10 minutes. Subsequently, 100 μL
30% trichloroacetic acid (TCAA) was added to 200 μL
sample, this was then vortexed and placed in a 50 °C
waterbath for 30 minutes. The tubes were then centri-
fuged at 12,000 rpm for 5 minutes. A total of 75 μL super-
natant was added to 75 μL Ehrlich reagent, in duplicate,
and measured with a spectrophotometer (Victor 1420
Multilabel Plate Reader; LKB-Wallac, Turku, Finland) at
an absorbance of 490 nm.
PGE2 ELISA
PGE2 secretion by ucMSC was analysed in ucMSC cul-
ture supernatant with the PGE2 High-sensitivity ELISA
Kit according to the manufacturer’s instructions (Enzo
Life Sciences BVBA, Antwerp, Belgium, ADI-930-001).
RT-PCR
UcMSC were seeded at 100,000 cells/well in 6-well
plates and stimulated with the various factors. At day 3,
supernatant was removed and cells were washed with
phosphate-buffered saline (PBS), RNA (Life Technologies)
was added later and the plates placed in the fridge. The
next day, mRNA was isolated with the use of the High
Pure RNA Isolation Kit (Roche Diagnostics, Basel,
Switzerland). mRNA was isolated from liver slices using
Trizol reagent (Invitrogen, Life Technologies, Carlsbad,
CA, USA). cDNA was synthesized from 500 ng mRNA
with random primers (Promega Benelux B.V., The
Netherlands). Quantitative gene expression was deter-
mined using TaqMan Gene Expression Master Mix (Life
Technologies) and assays-on-demand for IL-1RA
(Hs00893626_m1), MCP-1 (Mm00441242_m1), IL-6
(Mm00446190_m1), TNF-α (Mm00443258_m1) and IP-
10 (Mm00445235_m1). GAPDH (Hs 99999905_m1) was
used as housekeeping gene for analysing gene expression
of ucMSC. Data was expressed as the gene expression
relative to GAPDH and comparing fold changes to the
untreated MSC. Gene expression levels of the liver slices
are expressed as copy numbers (efficiency−ΔCt).
Isolation of PBMC
Peripheral blood samples were collected from living
kidney donors at Erasmus MC or isolated from buffy
coats obtained from Sanquin Blood Bank (Amsterdam,
Netherlands). Peripheral blood mononuclear cells
(PBMC) were isolated by density gradient centrifugation,
using Ficoll-Paque (GE Healthcare, Chicago, IL, USA)
and frozen at −180 °C until use.
CD107a NK cytotoxicity assay
For generation of activated NK cells, PBMCs were
thawed, washed and seeded at 100,000 cells/well in 96-
well plates. They were cultured in RPMI 1640 medium
(Life Technologies) with 1% penicillin/streptomycin so-
lution (P/S; 100 IU/ml penicillin, 100 IU/ml strepto-
mycin; Lonza), 10% heat-inactivated FBS (Lonza),
interleukin-2 (IL-2, 2.102 IU/ml; Peprotech) and
interleukin-15 (IL-15, 10 ng/ml; Peprotech). At day 7,
cells were collected and washed and NK cells were iso-
lated using a negative selection MACS procedure (NK
Cell Isolation Kit, human; MACS Miltenyi Biotec).
Following MACS and a washing step, the cells were left
overnight at 37 °C in a polystyrene tube with IL-2 and
IL-15.
MACS-sorted NK cells were added to pre-treated
ucMSC at a 4:1 ratio for 1 hour at 37 °C, together with
monensin (0.1 μL/200 μL/well; BD Golgistop; BD
Biosciences) and αCD107a antibody (LAMP-1, APC, BD
Pharmingen) in polypropylene tubes. The cells were then
washed and stained for CD3 (PERCP; BD Biosciences),
CD16 (PE; BD Biosciences) and CD56 (PE; BD
Biosciences) for 30 minutes at 4 °C. The cells were subse-
quently washed and analysed with the FACSCanto II flow
cytometer.
T cell proliferation assay
Pre-treated ucMSC were seeded into 96-well plates and
left overnight to adhere in the incubator. The next day,
PBMC were labelled with Cell Trace CFSE (Life
Technologies) according to the instructions of the
manufacturer and seeded on top of the ucMSC, at differ-
ent [MSC:PBMC] ratios: [1:10], [1:5] and [1:2.5]. αCD3/
CD28 stimulation was added (0.5 ug/ml αCD3 antibody,
0.5 μg/ml αCD28 antibody and 0.5 μg/ml goat-α-mouse
antibody; Life Technologies). The co-cultures were left
for 3 days and PBMC were collected. PBMC were
stained for CD4 (APC; eBioscience, San Diego, CA,
USA), CD8 (Pe-cy7; eBioscience) and intracellular IFN-γ
(Bv421; BD Biosciences). With the use of the FACS-
Canto II flow cytometer the proliferation of PBMCs was
measured.
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Carbon tetrachloride (CCl4) liver injury model
Healthy 8-week-old male C57BL/6 mice were purchased
from Charles River (Sulzfeld, Germany). The mice were
housed in a facility with a 12-hour light-dark cycle and
allowed free access to food and water. All the procedures
and animal housing conditions were carried out in strict
accordance with current EU legislation on animal ex-
perimentation and were approved by the Institutional
Committee for Animal Research (DEC protocol EMC
No. 127-12-14).
In the first set of experiments mice received either in-
traperitoneal (IP) CCl4 solution (4 μl/g bodyweight,
250 μl/ml mineral oil; 289116 Sigma-Aldrich) or mineral
oil for controls. Three hours after CCl4 injection pre-
treated ucMSC, which were labelled with Qtracker
beads, were infused intravenously (IV) in the tail vein in
200 μl suspension in PBS (250,000 cells/mice). Four
hours after ucMSC infusion, mice were sacrificed using
cardiac puncture under isoflurane anaesthesia (Additional
file 3: Figure S2 for experimental regimen). Whole mice
were embedded in mounting medium for cryotomy
(O.C.T. compound; VWR Chemicals, Radnor, PA, USA)
and put in liquid nitrogen until frozen. The whole mice
were then stored at -80 °C until shipment to BioInVision
(Cleveland, OH, USA) for imaging.
In the second set of experiments, mice receiving IP
CCl4 solution had a similar infusion of pre-treated
ucMSC 3 hours later. After 72 hours the mice were
sacrificed by cervical dislocation and blood and livers
were harvested and frozen until further use.
ALT measurement
Serum samples were thawed and centrifuged at
3000 rpm for 10 minutes. Thereafter, 50 μl of sample
was diluted 1:5 with MilliQ. ALT quantification was
done with an ALT measurement kit according to the in-
structions of the manufacturer (Roche Diagnostics;
04467388190). The samples were measured using a
Roche/Hitachi cobas c analyzer.
Labelling, quantification and visualization of MSC
Pre-treated ucMSC were collected using 0.05% trypsin-
EDTA (Life Technologies) and washed. Subsequently
they were labelled with Qtracker 605 cell labeling kit
beads according to the manufacturer’s instructions (Life
Technologies). UcMSC take up Qtracker 605 beads
during the labelling procedure. Post labelling, ucMSC
were washed to remove any beads that were not inter-
nalized by the ucMSC.
Three-dimensional anatomical and molecular fluores-
cence videos were generated of the frozen whole mice
samples by BioInVision Inc. with CryoViz™ technology.
The CryoViz™ technology picks up the signal of clusters
of Qtracker 605 beads, which are internalized in the
ucMSC. Cell counts were quantified using imaging
algorithms.
Ex vivo culture of liver slices
Mouse livers were obtained from healthy C57Bl/6 mice.
Directly after isolation, mouse livers were sliced into
150 μm thick slices with a diameter of 1 cm with Vibra-
tome (VT 1200S, Leica Biosystems, Wetzlar, Germany).
The slices were subsequently placed in 6-well plates con-
taining differently pre-treated MSC in high-glucose
DMEM with 10% serum, Additional file 4: Figure S3. In
addition, lipopolysaccharide [(LPS), 0.2 μg/ml; Sigma-
Aldrich] was added to the medium. The tissues were
kept overnight at 37 °C, 5% CO2 and 20% O2 on a
shaker (50 rpm). After 24 hours, supernatant was col-
lected and the liver slices were snap frozen.
Milliplex assay
Serum and tissue culture supernatant levels of IL-6, IL-
10, granulocyte colony-stimulating factor (G-CSF), inter-
feron gamma-induced protein 10 (IP-10), keratinocyte
chemoattractant chemokine (C-X-C motif ) ligand 1 (KC,
CXCL1), monocyte chemoattractant protein-1 (MCP-1,
also known as CCL2), macrophage inflammatory
protein-1 alpha (MIP-1α) and tumour necrosis factor
alpha (TNF-α) were measured using a Milliplex mouse
cytokine/chemokine magnetic bead panel multiplex
assay (Merck Millipore, Billerica, MA, USA) and Mouse
Premixed Multi-Analyte kit (Magnetic Luminex assay;
cat LXSAMSM; R&D Systems). The samples were
measured on the Luminex 100/200 cytometer (Luminex,
Austin, TX, USA) using Xponent software.
Statistical analysis
Data were analysed using IBM SPSS Statistics 21 (IBM
Corp., Armonk, NY, USA) and Prism software v5.04
(GraphPad Software Inc., La Jolla, CA, USA), herein
Mann-Whitney tests were performed. P values <0.05
were considered significant.
Results
Characterization of ucMSC
Flow cytometric analysis of ucMSC demonstrated ex-
pression of CD13, CD73, CD90 and CD105 and absence
of CD31 and CD45 (Additional file 5: Figure S4). This is
in line with the minimal ISSCT criteria and thus
confirming the MSC phenotype of the used cells.
Impact of pre-treatment of ucMSC on immunogenicity
and immunomodulatory phenotype
To modulate the immunomodulatory and immunogenic
phenotype of ucMSC in vitro, ucMSC were differentially
treated for 3 days and the expression of key immunomodula-
tory and immunogenicity molecules was examined (Table 1).
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Expression of HLA class I and II on the ucMSC cell sur-
face was used as a marker of ucMSC immunogenicity. The
percentage of HLA class I-expressing ucMSC increased
after treatment with IFN-γ (8-fold; p < 0.05), IFN-β (5-fold;
p < 0.05), Starv (2-fold; p < 0.05), VitB6 (7-fold; p < 0.05),
Starv + VitB6 (9-fold; p < 0.05), RA (4-fold; p < 0.05) and
MC (12-fold; p < 0.05) compared to untreated ucMSC. In
addition, treatment with IFN-γ, VitB6, Starv + VitB6 and
MC also increased the number of ucMSC expressing HLA
class II by 7- (p < 0.05), 3- (p < 0.05), 2- (p < 0.05) and 8-fold
(p < 0.05), respectively.
The number of ucMSC expressing the negative co-
stimulatory molecule PD-L1 increased with IFN-γ (96% ±
3; p < 0.05), Starv + VitB6 (72% ± 1; p < 0.05) and MC treat-
ment (97% ± 1; p < 0.05), compared to untreated ucMSC
(46% ± 6). In addition, expression levels of PD-L1 per
ucMSC were increased by IFN-γ (median fluorescence in-
tensity (MFI) = 1947 ± 263; p < 0.05), Starv + VitB6 (MFI =
755 ± 235; p < 0.05) and MC treatment (MFI = 1279 ± 216;
p < 0.05), with respect to untreated ucMSC (MFI = 219 ±
22) (data not shown in Table 1). All treatments preserved
the expression of CD73, which is involved in anti-
inflammatory adenosine production. Gene expression of
IL1RA showed trends of upregulation after VitB6 treat-
ment and the combined treatment of Starv + VitB6 (67-
(p < 0.05), and 507-fold increase (p < 0.05), respectively).
IFN-γ and MC treatment significantly upregulated IDO
activity of ucMSC 14-fold (p < 0.05) and 15-fold (p < 0.05),
respectively. IFN-γ treatment significantly reduced the se-
cretion of anti-inflammatory PGE2 compared to untreated
MSC (14-fold; p < 0.05).
Treatment with IL-7, IL-15, IL-17, budesonide, tres-
postinil, activin A and TNF-α showed no effect on any
of these parameters (Additional file 2: Table S1) and thus
the effects of these factors were not examined further.
IFN-β, TGFβ and MC treatment of ucMSC protects against
NK cell lysis
To investigate the effect of pre-treatment of ucMSC on
their susceptibility to NK cell lysis, the induction of
CD107a expression on NK cells by ucMSC was analysed.
The percentage of CD107a-expressing NK cells in-
creased from 13% ± 1 to 62% ± 4 (p < 0.05) when NK
cells were exposed to untreated ucMSC (Fig. 1), however
pre-treatment of ucMSC with IFN-β, TGFβ and MC
reduced the increase in CD107a expression on NK
cells to 45% ± 1 (p < 0.05), 51% ± 2 (p < 0.05) and 37% ± 1
(p < 0.05) respectively.
Pre-treated MSC inhibit T cell proliferation and IFN-γ
production
To examine the potential of MSC to inhibit CD4 and CD8
T cell proliferation and IFN-γ production, αCD3CD28-
activated PBMCs were co-cultured at different ratios with
pre-treated ucMSC. CD4 and CD8 T cell proliferation was
inhibited in a dose-dependent manner by all ucMSC
(Fig. 2a/b). UcMSC treated with IFN-γ and MC sup-
pressed CD4 and CD8 T cell proliferation more potently
than untreated MSC (Fig. 2a/b). However, none of the
pre-treated ucMSC was able to significantly reduce the
intracellular IFN-γ content of CD4 and CD8 T cells, com-
pared to the untreated MSC (Fig. 2c/d).
Effect of ucMSC in CCl4-induced liver inflammation model
To examine the immunomodulatory capacity of pre-
treated ucMSC in CCl4-treated mice, serum levels of
inflammatory associated cytokines MCP-1 and IP-10 were
measured 3 days after cell infusion (Fig. 3a/b). Whilst sig-
nificantly elevated levels were observed when comparing
healthy to liver-injured mice, no significant differences
were observed with ucMSC infusion. Similarly, infusion of
pre-treated ucMSC did not reduce ALT levels as a marker
of liver damage with respect to the CCL4 control or
compared to infusion with untreated ucMSC (Fig. 3c). As
no immunomodulation was observed; biodistribution of
ucMSC was subsequently examined.
Pre-treatment of ucMSC alters their retention and
biodistribution in vivo
UcMSC were labelled with Qtracker605 beads to enable
analysis of their biodistribution at a single cell level by
CryoViz imaging. Representative bright field and fluores-
cent images of ucMSC, 4 hours post labelling with
Qtracker605 beads are shown in Fig. 3e. Four hours after
infusion of 250,000 labelled ucMSC in CCl4-treated
mice, 51% of untreated ucMSC were detectable within
the mice (Fig. 3d/f ). The majority of these ucMSC were
located within the lungs (81%) with a small percentage
located within the liver (13%) (Fig. 3g/h). Pre-treatment
with MC (12%) led to a significantly lower distribution
of ucMSC to the lungs compared to untreated ucMSC
(81%) (Fig. 3g). Furthermore, a larger percentage of
TGFβ-treated MSC were found within mice (62%) com-
pared to untreated ucMSC, of which a larger percentage
were found in the liver (25%) compared to untreated
ucMSC (13%) (Fig. 3h). These observations were not a
consequence of cell size differences as MC- and TGFβ-
treated ucMSC were the same size as untreated ucMSC
(Additional file 6: Figure S5). Pre-treatment with IFN-γ,
IFN-β, Starvation, VitB6 and MC resulted in the detec-
tion of lower numbers of ucMSC 4 hours after adminis-
tration compared to untreated ucMSC (Fig. 3f ).
UcMSC(MC) resolve liver inflammation in an ex vivo liver
tissue model
As intravenously administered ucMSC poorly distribute
to the liver, we assessed the efficacy of ucMSC in ameli-
orating liver inflammation in an ex vivo liver tissue slice,
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where cells were placed in direct contact with injured
liver tissue. Significantly elevated gene expression levels
and secretion levels of inflammatory factors (MCP-1,
TNF-α, IL-6, IP-10 and CXCL1) were observed in the
diseased control liver tissue compared to the healthy
control (Fig. 4). Pre-treatment of MSC with MC resulted
in a marked reduction in expression levels of several in-
flammatory genes (MCP-1, TNF-α and IP-10), with more
limited effects seen on TNF-α ( ucMSC(IFN-β)) and IP-
10 (ucMSC(VitB6), ucMSC(starvation) and ucMSC(RA)).
Moreover, MC pre-treatment decreased secretion of
MCP-1, TNF-α, IL-6 and CXCL1 (all p < 0.05), whereas
RA pre-treatment only reduced TNF-α secretion.
Discussion
MSC have shown to be a promising cell type for treating
various immune disorders in numerous disease models
[3, 4, 19, 21, 22], including clinical trials of patients with
liver disease [7–13]. However, the immunosuppressive
effects of MSC need to be induced by inflammatory
stimulation, and MSC get trapped in the lungs after
intravenous infusion and have a short in vivo survival
time [29, 30]. Therefore, to enhance their therapeutic ef-
ficacy, improvement of their immunomodulatory prop-
erties and immunogenicity is necessary. The present
study demonstrates that ucMSC are responsive to a
variety of treatments, including inflammatory factors,
vitamins and serum-deprivation. Their responsiveness
may be employed to improve the properties of ucMSC
to generate cells with enhanced therapeutic efficacy.
In vitro experiments showed that treatment with IFN-
γ or MC, increases the immunosuppressive capacity of
ucMSC. In addition, treatment with IFN-β, TGFβ and
MC strongly decreases their susceptibility to lysis by NK
cells. In vivo tracking results showed differential effects
of the pre-treatments on the MSC’s biodistribution and
survival, where treatment with VitB6, Starv + VitB6 and
MC ensured rapid clearance while treatment with TGFβ
resulted in prolonged presence of ucMSC. No immuno-
modulatory effects were observed by pre-treated ucMSC
in a CCl4 liver inflammation model, possibly due to the
fact that the majority of the cells were trapped in the
lungs. In the ex vivo culture system in which liver slices
were cultured in the presence of ucMSC, significant
amelioration of the inflammation by ucMSC(MC) was
demonstrated by reduced inflammatory cytokine
production. In summary, most effectively, pre-treatment
of ucMSC with the multiple cytokine combination MC,
resulted in enhanced immunomodulation and reduced
immunogenicity.
Application of optimised ucMSC as an immunotherapy
depends on the therapeutic requirements necessary to
Fig. 1 CD107a-expressing NK cells after exposure to pre-treated ucMSC. a Representative FACS plots of CD107a expression on NK cells, without ucMSC
(left), with untreated ucMSC (middle), with IFN-γ-treated ucMSC (right) b Graph displaying boxplots of CD107a-expressing NK cells after exposure to the
various pre-treated MSC (untreated, IFN-γ, IFN-β, TGFβ, starvation, vitamin B6, Starv + VitB6, retinoic acid and combination IFN-γ + TGFβ + RA (MC)).
Results are shown as means ± SEM (n = 4). *Indicates significant difference (p < 0.05). IFN-γ interferon gamma, MC multiple cytokine cocktail, NK natural
killer cells, RA retinoic acid, Starv starvation, serum deprivation, TGFβ transforming growth factor beta, ucMSC umbilical cord-derived mesenchymal
stromal cells, VitB6 vitamin B6, pyridoxal hydrochloride
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target the disorder. For example, strong immunomodula-
tory properties in MSC such as high IDO activity are
favourable when helping graft acceptance after transplan-
tation [19]. Secretion of PGE2 and CCL2 has shown to be
important to attenuate sepsis, local inflammation and
mediates autoimmune disorders [3, 4, 21, 22]. In the
present study we observed that ucMSC are very suscep-
tible to treatment by IFN-γ and MC, whereby they are
induced into a strong immunomodulatory phenotype with
high IDO activity, PD-L1 expression and potential to
inhibit lymphocyte proliferation. Interestingly, in contrast
to IFN-γ treatment, MC treatment also decreases the
susceptibility of ucMSC to NK cell lysis and ameliorates
inflammation in liver tissue slices.
Our results demonstrate that the phenotype and
function of ucMSC is not fixed. Recently, we observed
that the lung microvasculature wherein MSC get trapped
initiate upregulation of various pathways in MSC and
thus alter their phenotype after infusion [42]. It is
conceivable that the induced changes by the various
pre-treatments will be influenced after infusion. The
interactions between pre-treated ucMSC and the micro-
environment are therefore a determinant on the effect-
iveness of these ucMSC.
Fig. 2 Inhibition of CD4 and CD8 T cell proliferation and intracellular IFN-γ production. MSC and αCD3CD28-stimulated and CSFE-labelled PBMCs
were co-cultured at different ratios for 7 days. Thereafter proliferation of a CD4 and b CD8 T cells was measured utilizing CFSE dilution with FACS.
Proliferation is expressed as the percentage of proliferating cells relative to the positive control in the absence of ucMSC. c IFN-γ production by
CD4 and d CD8 T cells was measured using FACS and an intracellular labelling of IFN-γ. The IFN-γ-containing CD4 and CD8 T cells are represented
as a percentage from the CD4 or CD8 T cell population. Results are shown as means ± SEM (n = 5). *Indicates significant difference (p < 0.05). IFN-γ
interferon gamma, MC multiple cytokine cocktail, PBMC peripheral blood mononuclear cells, RA retinoic acid, Starv starvation, serum deprivation,
TGFβ transforming growth factor beta, ucMSC umbilical cord-derived mesenchymal stromal cells, VitB6 vitamin B6, pyridoxal hydrochloride
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Efficacy of MSC therapy depends on various aspects,
one of which is the biodistribution of MSC after infusion.
Although no direct correlation has been established, it is
suggested that short-term effects of MSC are mediated by
their secretome and their long-term effects are a result of
activation and interaction with other cells types, via a hit-
Fig. 3 Effects on inflammation and liver damage in CCL4-induced liver injury and biodistribution of pre-treated MSC. Pretreated MSC were labelled
with fluorescent Qtracker 605 beads and intravenously infused in C57BL/6 mice. a Levels of MCP-1, b IP-10 and c ALT were measured in the serum
72 hours after ucMSC infusion. d Representative images of the biodistribution of pre-treated MSC in vivo 4 hours after ucMSC infusion. Yellow dots
correspond with a cluster of observed MSC. e Representative image of ucMSC labelled with Qtracker 605 beads, still visible in MSC 4 hours after
labelling. f Diagram showing the percentage of infused ucMSC 4 hours after administration. Figures (g) and (h) show the relative number of ucMSC
in lungs and liver, respectively, calculated from the total number of detected ucMSC. Results are shown as means ± SEM (n = 4). *Indicates significant
difference (p < 0.05) with respect to the CCL4 control. ALT alanine aminotransferase, CCl4 carbon tetrachloride, IFN-γ interferon gamma, MC multiple
cytokine cocktail, MCP-1 monocyte chemotactic protein-1, RA retinoic acid, Starv starvation, serum deprivation, TGFβ transforming growth factor beta,
ucMSC umbilical cord-derived mesenchymal stromal cells, VitB6 vitamin B6, pyridoxal hydrochloride
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and-run mechanism [3, 15, 18, 21, 43]. Thus, the biodistri-
bution of MSC determines which cell types they may
encounter and depending on the aim of the therapy a spe-
cific distribution will be favoured. Tracking of labelled
ucMSC by CryoViz enables in-depth visualization of MSC
after administration and subsequently gives an interpre-
tation of not only their biodistribution, but also their
survival. Previously, localization in the lungs and short
survival time of intravenously injected bone marrow-
derived MSC was observed [29]. The present study con-
firms that the majority of infused ucMSC accumulate in
the lungs and that there is a rapid clearance of cells. The
retainment of ucMSC was improved by pre-treatment
with TGFβ, which corresponds with the observed reduced
recognition of ucMSC(TGFβ) by NK cells in vitro. Inter-
estingly, ucMSC(TGFβ) showed no differences in their ex-
pression of HLA type I and II whereas they were less
recognized less by NK cells. This suggests that TGFβ po-
tentially modulates the expression of ligands on MSC that
were not analysed in this study (e.g. NKG2D, DNAM1
and natural cytotoxicity receptors [44–46]). Depending on
the therapeutic requirements, longevity or rapid clearance
of administered MSC may be desirable. Our results dem-
onstrate that longevity and biodistribution of MSC can be
modulated by pre-treatment of the cells.
Lack of immunomodulation by any of the pre-treated
ucMSC in vivo could be credited to the fact that the
ucMSC were unable to travel towards the liver. As for
Fig. 4 Effect of ucMSC on ex vivo liver slices. Gene expression levels and cytokine/chemokine levels were measured in liver slices treated with LPS and
supernatant, respectively. (a)(b)(c) Both gene expression levels and secretion levels were measured for MCP-1, TNF-α and IL-6. In addition, d gene expres-
sion levels of IP-10 and also e CXCL1 were measured in the medium. Results are shown as means ± SEM (n = 6). *Indicates significant difference (p< 0.05).
CXCL1 chemokine (C-X-C motif) ligand 1, IFN-γ interferon gamma, IL interleukin, IP-10 interferon gamma-induced protein 10, LPS lipopolysaccharide, MC
multiple cytokine cocktail, NK natural killer cells, RA retinoic acid, Starv starvation, serum deprivation, TGFβ transforming growth factor beta, TNF-α tumour
necrosis factor alpha, ucMSC umbilical cord-derived mesenchymal stromal cells, VitB6 vitamin B6, pyridoxal hydrochloride
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when the cells were in contact with targeted liver tissue,
in the inflammatory ex vivo model, strong amelioration
of the inflammation by ucMSC(MC) was observed. Pos-
sibly, this in vivo inflammatory liver model requires
ucMSC to be in direct contact with the tissue for them
to be able to exert their immunomodulatory capacities.
Therefore for future studies, administration of ucMSC
via the portal vein or hepatic artery may be a more effi-
cient approach for treatment of liver inflammation.
Conclusions
To conclude, these findings demonstrate that ucMSC are
responsive to in vitro treatment, whereby their immunomod-
ulatory properties and their immunogenicity can be differen-
tially modulated. TGFβ treatment of ucMSC reduced their
immunogenicity and altered their biodistribution and IFN-γ
treatment enhanced their immunomodulatory capacities.
Most interestingly, treatment with the multiple cytokine
combination MC resulted in reduced immunogenicity, in-
creased immunomodulatory capacity as well as enhanced
effectiveness to ameliorate liver inflammation. Therefore, in
vitro pre-treatment of ucMSC MC will make them more
suitable as an effective immunotherapy targeted for liver
inflammation.
Additional files
Additional file 1: Figure S1. Study design. This study is organized in
three sections: in vitro, in vivo and ex vivo. (TIF 6664 kb)
Additional file 2: Table S1. Key immunogenic and immunomodulatory
molecules after 3 days of in vitro treatment of ucMSC. The table displays
the mean ± SEM percentages of MSC expressing surface markers HLA
class –I and –II, PD-L1 and CD73, measured via flow cytometric analysis.
Mean ± SEM concentration of L-Kynurenine [µM] and PGE2 [ng/ml]. Fold
increase of IL1RA gene expression compared to unstimulated ucMSC.
n=5, no significant differences were observed. (DOCX 17 kb)
Additional file 3: Figure S2. In vivo experimental schemes. (Top) In the
first set of experiments mice were treated with CCl4 and 3 hours later
pre-treated ucMSC (untreated, IFN-γ, IFN-β, TGFβ, starvation, vitamin B6,
Starv + VitB6, RA and MC), which were labeled with Qtracker605 beads,
were infused IV. Four hours after ucMSC infusion the mice were sacrificed
and prepared for imaging. (Bottom) In the second set of experiments
mice were sacrificed 72 hours after CCL4 injection and serum was
collected. (TIF 7779 kb)
Additional file 4: Figure S3. Ex vivo experimental scheme. UcMSC
were pre-treated for 3 days. Medium was then refreshed and the cells
were left overnight in the incubator. The following day, livers were
collected from healthy C57BL/6 mice and directly after isolation cut into slices
(diameter = 1 cm and thickness = 150 μm) and placed in the wells on top of the
pre-treated ucMSC in the presence of LPS. The liver slices were left overnight in
the incubator on a shaker (50 rpm). After 24 hours, supernatant and liver slices
were harvested. (TIF 4600 kb)
Additional file 5: Figure S4. Characterization ucMSC by flow
cytometry. Representative histograms of expression of MSC markers
CD13, CD73, CD90, CD105 and negative expression of the endothelial
marker CD31 and hematopoietic marker CD45. Stained ucMSC (grey) and
isotype control (white). (TIF 30000 kb)
Additional file 6: Figure S5. MSC diameter. Measured diameter of
pre-treated ucMSC in micrometres. Results are shown as means ± SEM
(n = 5). *Indicates p < 0.05. (TIF 4687 kb)
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